Sofinnova Ventures Research
Investment Thesis
Sofinnova Ventures (operating today as "Sofinnova Investments," doing business at sofinnova.com) is a life sciences venture capital firm that partners with biopharmaceutical entrepreneurs from company inception through IPO and beyond. The firm's stated mission is "to improve the lives of patients through science," and it positions itself at the intersection of life science, finance, and innovation. Sofinnova deploys both human and financial capital — including deep operating experience from its executive partners and advisors — to guide founders through drug development, regulatory navigation, company building, and public market transitions. This is the U.S. entity of the Sofinnova family, distinct from the Paris-headquartered Sofinnova Partners (a separate firm since a 1997 restructuring), though both trace their roots to the original Sofinnova founded in Paris in 1972.
Sector Focus
Sofinnova invests exclusively in therapeutics and life sciences, with particular depth in oncology, immunology, neurology, ophthalmology, respiratory disease, dermatology, cardiometabolic disease, and women's health. Newer additions to the portfolio show growing interest in RNAi therapeutics, radiopharmaceuticals/radioligand therapy, gene therapy, and in vivo cell-engineering platforms (e.g., lipid nanoparticle RNA delivery). The firm does not invest outside biotech/life sciences — no software, consumer, or general enterprise technology.
Stage Focus
Sofinnova invests across the full company lifecycle: late-preclinical through clinical-stage private companies, and — since 2017 — public equity therapeutics (crossover and post-IPO public market investing via a dedicated Public Equity team). Typical entry points are Series A through Series C private rounds, plus IPO/crossover rounds and follow-on public offerings.
Check Size
Exact check-size ranges are not publicly disclosed. Individual disclosed rounds the firm has participated in span roughly $30M (early Series B, e.g. BioClin Therapeutics, 2017) to $215M+ (Avenzo/Rallybio concurrent placement, 2026), with the firm typically participating alongside 5-10 other institutional co-investors rather than writing the full round alone.
Lead Tendency
Mixed — Sofinnova both leads and follows. It led or co-led rounds such as Coultreon Biopharma's $125M Series A (April 2026, co-led with Forbion and Novo Holdings) and ARTBIO's $132M Series B (July 2025, co-led with B Capital), while participating as one of several syndicate members in others (City Therapeutics, Expedition Therapeutics, Claris Bio). Historically it has served as sole or co-lead investor on early rounds for many portfolio companies (e.g., BioClin Therapeutics Series B, 2017).
Recent Activity
Sofinnova has been consistently active through 2025-2026, deploying from its most recent flagship vehicle, Sofinnova Ventures Partners X ($650M, closed 2016), alongside its Public Equity strategy and a "Synergy Fund." As of Q3 2026 the firm reports approximately $4.6B in AUM and committed capital across its history. Recent financings include:
- Claris Bio $118M Series B (July 2026)
- Expedition Therapeutics $115M Series B, oversubscribed (August 2026)
- City Therapeutics $99.5M Series B for RNAi therapeutics (June 2026)
- Coultreon Biopharma $125M Series A, led (April 2026)
- Avenzo/Rallybio merger with $215M concurrent placement (June 2026)
- ARTBIO $132M Series B, co-led (July 2025)
- Capstan Therapeutics acquired by AbbVie for up to $2.1B (announced June 2025, closed August 2025)
- BioAge Labs upsized $115M public offering (January 2026)
Portfolio Highlights
Sofinnova's track record (as of March 31, 2026) spans 120+ companies funded, 55 IPOs, 33 M&A exits, and 36 FDA drug approvals. Notable exits and milestones include: RayzeBio (acquired by Bristol Myers Squibb, 2024), Karuna Therapeutics (acquired by Bristol Myers Squibb, 2024), Akouos (acquired by Eli Lilly, 2024), VelosBio (acquired by Merck), Gyroscope Therapeutics (acquired by Novartis), CinCor (acquired by AstraZeneca), Spark Therapeutics (acquired by Roche), Tesaro (acquired by GlaxoSmithKline), and Capstan Therapeutics (acquired by AbbVie, 2025). Public portfolio companies include Vera Therapeutics, Natera, Apellis Pharmaceuticals, Ascendis Pharma, Merus, and ArriVent BioPharma. Recent notable clinical wins include Vera Therapeutics' FDA accelerated approval for TRUTAKNA (IgA Nephropathy, July 2026) and Baxfendy's FDA approval as the first aldosterone synthase inhibitor (May 2026).
Team
Sofinnova is led by a partnership structure combining private-equity and public-equity investment teams plus a bench of executive partners with deep operating experience:
- Jim Healy, MD, PhD — Managing Partner
- Maha Katabi, PhD, CFA — General Partner
- Eric Delbridge, MD — General Partner, Public Equity
- Nathalie Auber — Partner & CFO
- Hooman Shahlavi — Partner & Chief Legal Officer
- Aneal Tenjarla — Partner, Associate Portfolio Manager, Public Equity
- Lars Ekman, MD, PhD — Executive Partner
- Jonathan Leff, MD — Executive Partner
- Chris Carpenter, MD, PhD — Executive Partner
- Jakob Dupont, MD — Executive Partner
- Maha Radhakrishnan, MD — Executive Partner (frequently the board observer on new financings, e.g. Claris Bio, City Therapeutics)
- David Kabakoff, PhD — Executive Advisor
- Perry Nisen, MD, PhD — Executive Advisor
- Troy Ignelzi — Executive Advisor
- Debbie Murray — Chief People Officer
- James Brody — Chief Compliance Officer & COO, Public Equity
Decision Process
Sofinnova operates as a multi-partner investment team (Managing Partner plus General Partners across private and public equity strategies) rather than a solo-GP structure. Executive Partners and Executive Advisors — many former biopharma C-suite operators — provide diligence and operational support alongside the core investment partnership, consistent with a partnership-style decision process.
Founder Preferences
The firm gravitates toward technical/scientific founding teams building differentiated therapeutic platforms or novel drug candidates with clear regulatory pathways, and it frequently backs founders through subsequent rounds, IPO, and post-IPO public offerings — reflecting a "company-building" orientation rather than pure early check-writing.
Geographic Focus
Primarily United States-based companies, with headquarters in Menlo Park, CA (3000 Sand Hill Road) and additional offices in Boston, MA and New York, NY. The portfolio is concentrated in major U.S. biotech hubs (Bay Area, Boston/Cambridge, San Diego) with occasional international portfolio companies (e.g., Coultreon Biopharma, Belgium).